Ani Patent-Cliff Exposure & CMS Drug Spending Portfolio
Ani (US): 13 reconciled FDA prescription therapies (0.5% 2025 to 2030 cliff risk), $128.3M 2024 CMS Part D & Medicaid spend, and $2,543 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 13 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.5% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $128.3M |
| 2024 Medicare Part D Spend | $112.0M |
| 2024 Medicaid Spend | $16.4M |
| California HCAI SB 17 Filings | Specialty launch notice ($2,543 intro WAC) |